No Data
Cabio Biotech(Wuhan) (688089.SH): Elect Yi Dewei to serve as the company's Director.
On December 26, Gelonghui reported that Cabio Biotech (Wuhan) (688089.SH) announced that on December 26, 2024, the company will hold the first meeting of the fourth Board of Directors, where all directors unanimously elected Mr. Yi Dewei as the chairman of the company, and Mr. Du Bin as the vice chairman, with terms effective from the approval of this Board of Directors until the term of the fourth Board of Directors expires.
Cabio Biotech(Wuhan) (688089.SH): First share buyback of 0.25 million company shares.
On December 26, Gelonghui reported that Cabio Biotech (Wuhan) (688089.SH) announced that on December 25, 2024, the company repurchased its shares for the first time through the Shanghai Stock Exchange trading system using a centralized bidding trading method. As of December 26, 2024, the company has cumulatively repurchased 250,000 shares via a dedicated securities account for share repurchase through centralized bidding, accounting for 0.149% of the company's current total share capital, with a highest Fill Price of 19.50 yuan/share, a lowest Fill Price of 19.14 yuan/share, and a total transaction amount of 4,855,735.67 yuan (excluding stamp tax.
cabio biotech(wuhan) (688089.SH): has not yet involved in NMN related technology and research
Glonghui, on November 19, announced that cabio biotech (wuhan) (688089.SH) stated on the interactive platform that the company uses synthetic biology as the underlying technology and cell factories as the preparation method, providing high-quality nutrient products and innovative solutions for clients in the global nutrition and health sectors through sustainable biomanufacturing. The main products currently include polyunsaturated fatty acids ARA, algal oil DHA, terpenoids β-carotene, astaxanthin, carbohydrate substances SA, and HMOs, widely used in infant formula, health foods, animal nutrition, personal care, and beauty fields, and based on synthesis.
Cabio Biotech (Wuhan) (688089.SH): Currently equipped with small AIGC for fine-tuning training.
Gallop meeting on November 19th: Cabio Biotech(Wuhan) (688089.SH) stated on the interactive platform that, regarding the application of artificial intelligence in research and development, the company has explored the fields of synthetic biology and artificial intelligence. Currently, it has a small AIGC that can be fine-tuned through training. It can be specifically applied to organizing experimental reports, initial design of technical solutions, construction of literature knowledge graphs, and monitoring of product information markets. This helps improve the efficiency and quality of research and development, promotes the intelligence and automation of scientific research work, and provides strong intellectual support for R&D activities.
cabio biotech(wuhan) (688089.SH): LNnT has completed small-scale trial fermentation process optimization and entered the pilot phase
gelonhui November 19th cabio biotech(wuhan) (688089.SH) stated on the interactive platform that the company has already developed a series of HMOs products including 2’-FL, 3-FL, 3’-SL, 6’-SL, LNnT, and related patents. According to the company's disclosed 2024 interim report, LNnT has completed small-scale fermentation process optimization and entered the pilot phase. Other company-related patents are not related to the company.
Jia Biyou: Jia Biyou Biotechnology (Wuhan) Co., Ltd. Report for the third quarter of 2024
No Data
